Table 1.
Average discount rates across subjects
| Placebo |
Propranolol |
|||||
|---|---|---|---|---|---|---|
| Condition | Mean (SEM) | Delay at which 50% SV lost (days) | % SV remaining after 1 year | Mean (SEM) | Delay at which 50% SV lost (days) | % SV remaining after 1 year |
| Delay Vary | 0.040 (0.008) | 25 | 6.4 | 0.031 (0.007) | 32.26 | 8.12 |
| Delay Vary (low Effective Dose) | 0.041 (0.012) | 24.39 | 6.26 | 0.035 (0.009) | 28.57 | 7.26 |
| Delay Vary (high Effective Dose) | 0.038 (0.010) | 26.32 | 6.72 | 0.026 (0.009) | 38.46 | 9.53 |
| Immediate Vary | 0.027 (0.005) | 37.04 | 9.21 | 0.020 (0.003) | 50 | 12.05 |
| Immediate Vary (low Effective Dose) | 0.032 (0.009) | 31.25 | 7.89 | 0.020 (0.003) | 50 | 12.05 |
| Immediate Vary (high Effective Dose) | 0.020 (0.005) | 50 | 12.05 | 0.020 (0.005) | 50 | 12.05 |
| Overall | 0.030 (0.005) | 33.33 | 8.37 | 0.024 (0.004) | 41.67 | 10.25 |
| Overall (low Effective Dose) | 0.034 (0.008) | 29.41 | 7.46 | 0.025 (0.005) | 40 | 9.88 |
| Overall (high Effective Dose) | 0.025 (0.005) | 40 | 9.88 | 0.023 (0.006) | 43.48 | 10.64 |
Note: Average hyperbolic discount rates across subjects, the delays at which 50% of the subjective value (SV) of the delayed reward has decreased (implied by the average discount rates) and the percent SV remaining after 1 year (implied by the average discount rates; N = 26). We also include these values separately for participants with high and low effective dose of propranolol (median split).